ArticleEuropean journal of nuclear medicine and molecular imaging2021
Interim [
Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Prognostic value of different metabolic response criteria in patients with advanced melanoma treated with immunotherapy: a comparative analysis of PECRIT, PERCIMT, and EORTC criteria.European journal of nuclear medicine and molecular imaging · 2026Article
- Applications and research progress of PET/CT in dynamic monitoring of immunotherapy in melanoma.Journal of translational medicine · 2026Review
- Baseline and earlyCancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Role ofWorld journal of nuclear medicine · 2023Article
- Predictive value and accuracy of [European journal of nuclear medicine and molecular imaging · 2023Article
- Advancements in dendritic cell vaccination: enhancing efficacy and optimizing combinatorial strategies for the treatment of glioblastoma.Frontiers in neurology · 2023Review
- The role ofFrontiers in immunology · 2023Article
- Prognostic value of immunotherapy-induced organ inflammation assessed onEuropean journal of nuclear medicine and molecular imaging · 2022Article
- Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [European journal of nuclear medicine and molecular imaging · 2022Article
- Pharmacokinetic studies of [European journal of nuclear medicine and molecular imaging · 2021Article
- Article
- Assessment of early metabolic progression in melanoma patients under immunotherapy: anEJNMMI research · 2021Article
- Article
- Quantitative DynamicCancers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn an attempt to identify biomarkers that can reliably predict long-term outcomes to immunotherapy in metastatic melanoma, we investigated the prognostic role of [
methodsTwenty-five patients with stage IV melanoma, scheduled for treatment with PD-1 inhibitors, were enrolled in the study (pembrolizumab, n = 8 patients; nivolumab, n = 4 patients; nivolumab/ipilimumab, 13 patients). [
resultsMedian follow-up from interim PET/CT was 24.2 months (19.3-41.7 months). According to the EORTC criteria, 14 patients showed MB (1 CMR, 6 PMR, and 7 SMD), while 11 patients showed no-MB (PMD). Respectively, the application of the PERCIMT criteria revealed that 19 patients had MB (1 CMR, 6 PMR, and 12 SMD), and 6 of them had no-MB (PMD). With regard to PFS, no significant difference was observed between patients with MB and no-MB on interim PET/CT according to the EORTC criteria (p = 0.088). In contrary, according to the PERCIMT criteria, patients demonstrating MB had a significantly longer PFS than those showing no-MB (p = 0.045). The emergence of radiologic irAEs (n = 11 patients) was not associated with a significant survival benefit. Regarding the sub-cohort undergoing also a third PET/CT, 14/17 patients (82%) showed concordant responses and 3/17 (18%) had a mismatch of response assessment between interim and late PET/CT.
conclusionPET/CT-based response of metastatic melanoma to PD-1 blockade after application of the recently proposed PERCIMT criteria is significantly correlated with PFS. This highlights the potential ability of [
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.